Clinical Research Directory

Inclusion criteria : * Aged 18 years or older * Hospitalized in intensive care for less than 96 hours * Presenting with septic shock evolving for less than 24 hours defined by: 1. Clinically or microbiologically documented infection and 2. SOFA score ≥ 2 or an increase in SOFA score ≥ 2 points if organ dysfunction was present before the infection and 3. Need for vasopressor administration to maintain a mean arterial pressure ≥ 65mmHg and 4. Lactate level \> 2mmol/L (18mg/dL) despite adequate fluid resuscitation * Patient's consent, their next of kin consent, or emergency inclusion Non inclusion criteria : * Chronic long-term antiepileptic treatment upon admission or patient with uncontrolled seizures * Chronic or progressive central neurological pathologies of traumatic, inflammatory, vascular, infectious, neoplastic, or degenerative origin, defined by cognitive impairments preventing independent living or an IQCODE score \> 4.5 * Patient with moderate to severe dementia * Patient with psychiatric history and/or suicide attempts * Severe head trauma within the past 3 months * Patients with limitations on active therapies or for whom therapeutic commitment is not maximal * Patient presenting a prolonged QTc interval on ECG and/or at risk of cardiovascular disease * Concomitant treatment with Methotrexate during the administration of the investigational treatment * Allergy to levetiracetam * Minor patients * Ongoing pregnancy (blood or urinary βHCG) * Breastfeeding women * Patients under guardianship or trusteeship * Non-affiliation with social security or CMU * Participation in another interventional trial with a drug that may interact with levetiracetam or may impact the evaluation of KiSS trial outcomes. In case of doubt, please contact the trial's coordinating investigator.